Centric Wealth Management Has $2.28 Million Holdings in Pfizer Inc. (NYSE:PFE)

Centric Wealth Management boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 175.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 85,997 shares of the biopharmaceutical company's stock after acquiring an additional 54,736 shares during the period. Centric Wealth Management's holdings in Pfizer were worth $2,282,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nordea Investment Management AB raised its stake in shares of Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after buying an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI raised its position in shares of Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock valued at $7,820,000 after acquiring an additional 159,984 shares during the last quarter. NFJ Investment Group LLC lifted its stake in shares of Pfizer by 12.8% in the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock valued at $11,129,000 after purchasing an additional 43,719 shares during the period. Copley Financial Group Inc. acquired a new position in shares of Pfizer in the 3rd quarter valued at $577,000. Finally, Zacks Investment Management boosted its position in shares of Pfizer by 10.9% in the 3rd quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock worth $69,142,000 after purchasing an additional 235,243 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.06% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on PFE shares. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Finally, Bank of America reissued a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Stock Down 1.6 %

Shares of PFE stock traded down $0.39 on Thursday, hitting $24.32. 37,619,637 shares of the stock were exchanged, compared to its average volume of 39,249,333. The business has a 50-day moving average of $25.98 and a 200 day moving average of $26.83. Pfizer Inc. has a fifty-two week low of $24.31 and a fifty-two week high of $31.54. The firm has a market capitalization of $137.90 billion, a P/E ratio of 17.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the firm posted $0.10 EPS. The business's revenue was up 24.7% on a year-over-year basis. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.